Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases

Zeitschrift fur Kardiologie

Volumn 93, Issue 6, 2004, Pages 439-453

  Stanger, O ^a   Herrmann, W ^b   Pietrzik, K ^c   Fowler, B ^d   Geisel, J ^b   Dierkes, J ^e   Weger, M ^f  

^a Salzburger Landeskliniken   (Austria)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f Universitats Augenklinik   (Austria)

Author keywords

Folate; Homocysteine; Hyperhomocysteinemia; Therapy; Vitamin B12

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; VITAMIN B GROUP;

AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEVELOPED COUNTRY; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; RISK ASSESSMENT; THROMBOSIS; VITAMIN SUPPLEMENTATION;

EID: 3042766490     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-004-0075-3     Document Type: Review

References (113)

1. Andersson A, Isaksson A, Brattstrom L, Hultberg B (1993) Homocysteine and other thiols determined in plasma by HPLC and thiol-specific post-column derivatization. Clin Chem 39:1590-1597
2. Bailey LB (1998) Dietary reference intakes for folate: the debut of dietary folate equivalents. Nutr Rev 56:294-299
3. Becker A, Kostense PJ, Bos G, Heine RJ, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD (2003) Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med 253:293-300
4. Beitz R, Mensink GB, Fischer B, Thamm M (2002) Vitamins-dietary intake and intake from dietary supplements in Germany. Eur J Clin Nutr 56:539-545
5. 6. Proc Nutr Soc 53:625-630
6. 6 safety issues. Ann N Y Acad Sci 585:321-330
7. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA (1999) Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 131:352-355
8. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE (1999) Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 159:38-44
9. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 274:1049-1057
10. Butterworth CE, Tamura T (1989) Folic acid safety and toxicity: a brief review. Am J Clin Nutr 50:353-358
11. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 15:136-143
12. Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, Green R, Kruger WD, Garrow TA, Jacobsen DW (1999) Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 39:93-109
13. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP (1996) S-Adenosylmethionine and methylation. FASEB J 10:471-480
14. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 5:249-255
15. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149-1155
16. Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I, Jacques P, Breteler MM, Holman R (2001) Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 8:363-369
17. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341-353
18. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw KT (1998) Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clin Chem 44:102-107
19. De Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP (1997) Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 51:643-660
20. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ (2002) Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 54:599-618
21. De Bree A, Verschuren WM, Kromhout D, Mennen LI, Blom HJ (2002) Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects. Int J Epidemiol 31:1268-1272
22. Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM (1998) Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80:874-877
23. Ducros V, Candito M, Causse E, Couderc R, Demuth K, Diop ME (2002) Comparison of plasma total homocysteine determinations in 9 french hospital laboratories by using 6 differents methods. Ann Biol Clin 60:421-428
24. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J (2001) Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 21:1196-1202
25. Doshi SN, Moat SJ, McDowell IF, Lewis MJ, Goodfellow J (2002) Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? Atherosclerosis 165:1-3
26. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D (2001) Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 81:645-672
27. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, Mark DB (2001) Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 39:824-835
28. Erbel R, Siffert W, Mohlenkamp S, Schmermund A (2003) Prevention der KHK durch Risikostratifizierung. Dtsch Med Wochenschr 128:330-336
29. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J 22:554-572
30. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL (2000) Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 20:493-499
31. Ford ES, Byers TE, Giles WH (1998) Serum folate and chronic disease risk: findings from a cohort of United States adults. Int J Epidemiol 27:592-598
32. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113
33. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH (1997) Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 43:141-145
34. Genest J Jr (1999) Hyperhomocyst(e)inemia-determining factors and treatment. Can J Cardiol 15:35B-38B
35. Graham I (1999) Homocysteine in health and disease. Ann Intern Med 131:387-388
36. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 277:1775-1781
37. 6 in foods. Nutr Rev 39:1-8
38. 12: plant sources, requirements, and assay. Am J Clin Nutr 48(Suppl 3):852-858
39. Herrmann W, Schorr H, Bodis M, Knapp JP, Muller A, Stein G, Geisel J (2000) Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. Eur J Clin Invest 30:1083-1089
40. Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295-300
41. Höher M, Hombach V (1998) Klinische und ökonomische Kosten-Nutzen-Relation bei der Behandlung von Patienten mit koronarer Herzerkrankung. Z Kardiol 87(Suppl 2):8-19
42. Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 316:894-898
43. Jacobsen DW (1998) Homocysteine and vitamins in cardiovascular disease. Clin Chem 44:1833-1843
44. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9
45. Kang SS, Wong PW, Malinow MR (1992) Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 12:279-298
46. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K (2003) American heart association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107:1562-1566
47. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL (2002) Homocysteine, MTHFR 677C → T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 59:529-536
48. Kim Yi (1999) Folate and carcinogesis: evidence, mechanisms, and implications. J Nutr Biochem 10:66-88
49. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group (2002) MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. J Am Med Assoc 288:2023-2031
50. Klever-Deichert G, Hinzpeter B, Wendland G, Lauterbach K (2000) Kosten-Nutzen-Analyse einer evidenzbasierten Sekundärprävention koronarer Herzkrankheiten durch Statine. Med Klin 95:305-313
51. Koenig W (1998) Epidemiologie der koronaren Herzkrankheit. Z Kardiol 87(Suppl 2):3-7
52. Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE (2000) Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study. Arch Intern Med 160:961-964
53. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA (1996) Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 5:1867-1874
54. Lewis CJ, Crane NT, Wilson DB, Yetley EA (1999) Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am J Clin Nutr 70:198-207
55. Liu JL, Maniadakis N, Gray A, Rayner M (2002) The economic burden of coronary heart disease in the UK. Heart 88:597-603
56. Lloyd-Jones DM, Larson MG, Beiser A, Levy D (1999) Lifetime risk of developing coronary heart disease. Lancet 353:89-92
57. Loria CM, Ingram DD, Feldman JJ, Wright JD, Madans JH (2000) Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 160:3258-3262
58. Malinow MR, Bostom AG, Krauss RM (1999) Homocyst(e)ine, diet, and cardiovascular diseases: a statement for Healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99:178-182
59. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G (1993) Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 87:1107-1113
60. Martin SC, Tsakas-Ampatzis I, Bartlett WA, Jones AF (1999) Measurement of plasma total homocysteine by HPLC with coulometric detection. Clin Chem 45:150-152
61. Martin JA, Smith BL, Mathews TJ, Ventura SJ (1999) Births and deaths: preliminary data for 1998. National Vital Statistics Reports 47:1-48
62. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP (2000) Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 72(Suppl 5):1307S-1315S
63. Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE, Vollset SE, Donohue C, Giesendorf B, Graham IM, Ulvik A, Zhang Y, Bjorke Monsen AL (2003) Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr 77:63-70
64. Moghadasian MH, McManus BM, Frohlich JJ (1997) Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 57:2299-2308
65. Nallamothu BK, Fendrick AM, Omenn GS (2002) Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia. Pharmacoeconomics 20:429-442
66. Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS (2000) Potential clinical and economic effects of homocyst(e)ine lowering. Arch Intern Med 160:3406-3412
67. Nexo E, Engbaek F, Ueland PM, Westby C, O'Gorman P, Johnston C, Kase BF, Guttormsen AB, Alfheim I (2000) Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine. Clin Chem 46:1150-1156
68. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Ueland PM (2002) Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med 162:1374-1381
69. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236
70. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 274:1526-1533
71. Oakley GP (1998) Eat right and take a multivitamin. N Engl J Med 338:1060-1061
72. Obeid R, Hakki T, Jouma M, Herrmann W (2003) The risk of venous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status. Clin Chem Lab Med 41:1357-1362
73. O'Callaghan P, Meleady R, Fitzgerald T, Graham I; European COMAC group (2002) Smoking and plasma homocysteine. Eur Heart J 23:1580-1586
74. Omenn GS, Beresford SA, Motulsky AG (1998) Preventing coronary heart disease: B vitamins and homocysteine. Circulation 97:421-424
75. Peterson JC, Spence JD (1998) Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 351:263
76. Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW (1999) Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin Chem 45:1261-1268
77. Quere I, Perneger TV, Zittoun J, Bellet H, Gris JC, Daures JP (2000) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 359:747-752
78. Refsum H, Helland S, Ueland PM (1985) Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 31:624-628
79. Refsum H, Ueland PM, Nygrd O, Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49:31-62
80. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ (1997) Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95:1777-1782
81. 6 from diet and supplements in relation to risk of coronary heart disease among women. J Am Med Assoc 279:359-364
82. 6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 97:437-443
83. Romano PS, Waitzman NJ, Scheffler RM, Pi RD (1995) Folic acid fortification of grain: an economic analysis. Am J Public Health 85:667-676
84. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809
85. Sans S, Kesteloot H, Kromhout D (1997) The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 18:1231-1248
86. Savage DG, Lindenbaum J, Stabler SP, Allen RH (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96:239-246
87. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. J Am Med Assoc 288:973-979
88. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593-1600
89. Schroeder HA (1971) Losses of vitamins and trace minerals resulting from processing and preservation of foods. Am J Clin Nutr 24:562-573
90. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 270:2693-2698
91. 12-folate interrelationships. Annu Rev Nutr 5:115-141
92. Shipchandler MT, Moore EG (1995) Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem 41:991-994
93. Smith SC Jr, Greenland P, Grundy SM (2000 ) AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. Circulation 101:111-116
94. Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81:3404-3413
95. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 268:877-881
96. Stanger O (2002) Physiology of folic acid in health and disease. Curr Drug Metab 3:211-223
97. Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC (2002) Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. J Pharmacol Exp Ther 303:158-162
98. Stanger O, Weger M, Renner W, Konetschny R (2001) Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 39:725-733
99. Stanger O, Weger M (2003) Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 41:1444-1454
100. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L, Goldman L (2001) Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. J Am Med Assoc 286:936-943
101. Tsimikas S, Witztum JL (2002) Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. J Am Coll Cardiol 40:2122-2124
102. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J (1996) Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. J Am Med Assoc 276:1879-1885
103. 6 status on homocysteine metabolism. J Clin Invest 98:177-184
104. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH (1993) Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39:1764-1779
105. Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324-332
106. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT (2001) Low dietary folate intake is associated with an excess incidence of acute coronary events: the kuopio ischemic heart disease risk factor study. Circulation 103:2674-2680
107. Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325:1202-1208
108. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM (1998) Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 158:862-867
109. Wilcken DE, Wilcken B (1997) The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20:295-300
110. Willems FF, Aengevaeren WR, Boers GH, Blom HJ, Verbeugt FW (2002) Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 40:766-772
111. 12) increases risk for spina bifida. Mol Genet Metab 67:317-323
112. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS (1999) Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 34:2002-2006
113. 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. Am J Ther 4:275-281